PT Bundamedik Tbk

Jakarta Stock Exchange BMHS.JK

PT Bundamedik Tbk EBT Margin for the year ending December 31, 2023: 2.71%

PT Bundamedik Tbk EBT Margin is 2.71% for the year ending December 31, 2023, a -74.58% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.
  • PT Bundamedik Tbk EBT Margin for the year ending December 31, 2022 was 10.66%, a -54.29% change year over year.
  • PT Bundamedik Tbk EBT Margin for the year ending December 31, 2021 was 23.32%, a 84.64% change year over year.
  • PT Bundamedik Tbk EBT Margin for the year ending December 31, 2020 was 12.63%, a 168.15% change year over year.
  • PT Bundamedik Tbk EBT Margin for the year ending December 31, 2019 was 4.71%, a 66.47% change year over year.
Key data
Date EBT Margin Net Income Margin EBITDA Margin EBIT Margin
Market news
Loading...
SV Wall Street
Jakarta Stock Exchange: BMHS.JK

PT Bundamedik Tbk

CEO Mr. Agus Heru Darjono
IPO Date July 6, 2021
Location Indonesia
Headquarters Jl. Teuku Cik Ditiro No.28
Employees 1,434
Sector Health Care
Industries
Description

PT Bundamedik Tbk provides health care services in Indonesia. As of December 31, 2021, the company operated 2 maternal and child hospitals, 3 general hospitals, 2 clinics, 10 IVF clinics, and 14 diagnostic laboratories. It also engages in the distribution of drugs, pharmaceuticals, and medical devices; and hotel, medical tourism, and management consulting businesses. The company was founded in 1973 and is headquartered in Jakarta Pusat, Indonesia. PT Bunda Medik is a subsidiary of PT Bunda Investama Indonesia.

Similar companies

HEAL.JK

PT Medikaloka Hermina Tbk

USD 0.09

0.97%

MIKA.JK

PT Mitra Keluarga Karyasehat Tbk

USD 0.15

0.79%

PRDA.JK

PT Prodia Widyahusada Tbk

USD 0.16

2.43%

DGNS.JK

PT Diagnos Laboratorium Utama Tbk

USD 0.01

-0.48%

SAME.JK

PT Sarana Meditama Metropolitan Tbk

USD 0.02

1.64%

StockViz Staff

January 31, 2025

Any question? Send us an email